Skip to main content

Eating More Nuts Could Protect Against Type 2 Diabetes

Eating a diet rich in omega-6 polyunsaturated fatty acids (PUFAs), which are found in soybean and sunflower oils, as well as in nuts, may protect against the development of type 2 diabetes, say an international team of researchers.
Pooling data on levels of linoleic acid and its metabolite arachidonic acid in almost 40,000 individuals from 10 countries, they found that those with the highest linoleic acid levels had a 35% reduction in the risk of developing type 2 diabetes compared with those with the lowest levels.
The research was published online in Lancet Diabetes & Endocrinology on October 11.
The results indicate that a "simple change in diet" may help protect against type 2 diabetes, said lead author Jason HY Wu, PhD, the George Institute for Global Health, University of New South Wales, Sydney, Australia, in a press release from his institution.
Current US guidelines recommend that between 5% and 10% of energy consumption come from linoleic acid. However, it has been suggested that this may be harmful either because it competes with omega-3 PUFAs or due to potential harmful effects of arachidonic acid.
Dr Wu acknowledges that some scientists have theorized that omega-6 is harmful to health. "But based on this large global study, we have demonstrated little evidence for harms and indeed found that the major omega-6 fat is linked to lower risk of type 2 diabetes."
Dariush Mozaffarian, MD, Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, who was senior author on the paper, added: "This is striking evidence."
"The people involved in the study were generally healthy and were not given specific guidance on what to eat. Yet those who had the highest levels of blood omega-6 markers had a much lower chance of developing type 2 diabetes."

Linolenic-Acid Levels Inversely Associated With Type 2 Diabetes Risk

Noting a recent meta-analysis indicating that total PUFA consumption improves both glycemia and insulin resistance (PLOS Med. 2016; DOI:10.1371/journal.pmed.1002087), the team conducted a search of the MEDLINE database and relevant reference lists for studies published on the impact of linoleic acid and arachidonic acid levels on the risk of incident type 2 diabetes.
They contacted the authors of the 26 prospective cohort studies identified by the search, of whom 20 agreed to take part in a harmonized, individual-level analysis. This yielded a total of 39,740 adults from 20 cohorts in the United States, Iceland, the Netherlands, Germany, Finland, the United Kingdom, Sweden, France, Australia, and Taiwan, none of whom had type 2 diabetes at baseline.
Biomarkers were sampled between 1970 and 2010 from phospholipids, total plasma or serum, cholesterol esters, and/or adipose tissue, with measurements performed in more than two lipid compartments in six cohorts.
The mean patient age ranged from 49 to 76 years, and the mean body mass index (BMI) ranged from 23.3 kg/m2 to 28.4 kg/m2.
Over 366,073 person-years of follow-up, 4347 individuals developed type 2 diabetes.
Multivariate analysis of the pooled data indicate that linoleic-acid levels were inversely associated with the risk of developing incident type 2 diabetes on continuous analyses, at a risk ratio per interquintile range of 0.65 (P < .001), and moderate heterogeneity (P = .002).
The team notes that the findings were generally similar across different lipid compartments, including phospholipids, plasma, cholesterol esters, and adipose tissue.
In contrast, levels of arachidonic acid were, overall, not significantly associated with the risk of developing type 2 diabetes, at a risk ratio per interquintile range of 0.96 (P = .38; P heterogeneity < .0001).
An exception was seen, however, for arachidonic acid levels in total plasma, at a risk ratio of 0.73 (P = .0003).
The analysis also demonstrated that the findings were not significantly affected by taking into account potential confounding factors, such as age, BMI, sex, race, aspirin use, omega-3 PUFA levels, or variants in the fatty-acid desaturase (FADS) gene, which is strongly associated with omega-6 PUFA levels.

A "Step Forward" for Linoleic Acid and " Reassuring" Data on Arachidonic Acid

The team says: "The prevalence of type 2 diabetes is escalating rapidly around the world, so identification of dietary and other modifiable risk factors for the prevention of the disease is of clinical, scientific, and public-health importance."
They continue: "Our analysis provides novel findings that, when combined with in vitro experimental and shorter-term interventions for metabolic risk factors, suggest that linoleic acid has an additional role for prevention of type 2 diabetes in healthy populations."
In addition, "our findings do not corroborate concerns about potential harmful effects of arachidonic acid."
In an accompanying comment, Gabriele Riccardi, MD, department of clinical medicine and surgery, Federico II University, Naples, Italy, says that the findings represent "a step forward" in the evidence supporting the idea that linoleic acid protects against type 2 diabetes.
He notes: "Although this finding cannot immediately be extrapolated to linoleic-acid intake, it seems reasonable to assume that the differences in the linoleic-acid biomarker associated with this outcome would be consistent with linoleic-acid intake corresponding to one serving of nuts or one spoonful of sunflower or corn oil daily.
"Epidemiological studies have shown that this amount of linoleic acid is associated with a reduced risk of type 2 diabetes."
Moreover, given the previous concerns over whether arachidonic acid may cause harmful effects, Dr Riccardi describes the finding that arachidonic-acid biomarkers are not associated with increased type 2 diabetes risk as "reassuring in view of the potential implications for dietary advice."
"Altogether, the outcomes of the study by Wu and colleagues are fully concordant with a nested case-cohort analysis of the European EPIC cohort [PLOS Med. 2016; DOI:10.1371/journal.pmed.1002094].  Together, these studies indicate that the association between higher linoleic-acid biomarkers and reduced risk of type 2 diabetes does not represent a chance finding.
"The effect of dietary linoleic acid on diabetes incidence should now be tested in a randomized, controlled intervention trial," he concludes.
Cohorts within the Fatty Acids and Outcomes Research Consortium received direct funding from a number of sources. Unilever also provided Tufts University (Massachusetts) with a restricted grant to partly support the analysis. Dr Wu received research grants from Unilever for this study. Dr Mozaffarian received ad hoc honoraria and consulting fees from the Life Sciences Research Organization, AstraZeneca, Boston Heart Diagnostics, Global Organization for EPA and DHA Omega-3, DSM, Nutrition Impact, the Haas Avocado Board, and Pollock Communications; and chapter royalties from UpToDate. Disclosures for the coauthors are listed in the paper. Dr Riccardi has no relevant financial relationships.
Lancet Diabetes Endocrinol. Published online October 11, 2017. Article, Editorial

Comments

Post a Comment

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more